TNF and psoriasis: At present, three main biologics, i.e., etanercept, infliximab, and adalimumab, are used to treat psoriasis by targeting TNFα to prevent TNF-mediated cellular responses and modulate biological responses that are controlled by additional downstream molecules induced or regulated by TNFs.